Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.

ABSTRACT:

Background

The COVID-19 pandemic has exacerbated the opioid crisis. Opioid-related deaths have increased and access to treatment services, including opioid agonist treatment (OAT), has been disrupted. The Ontario COVID-19 OAT Treatment Guidance document was developed to facilitate access to OAT and continuity of care during the pandemic, while supporting physical distancing measures. In particular, the Guidance expanded access to unsupervised OAT dosing. It is important to evaluate the changes in unsupervised OAT dosing after the release of the Ontario COVID-19 OAT Guidance based on patients' and prescribers' reports.

Method

Online questionnaires were developed collaboratively with people with lived and living expertise, prescribers, clinical experts, and researchers. Patien

SUBMITTER: Corace K 

PROVIDER: S-EPMC8695187 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature